CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation - Wikidata - wikimedia - TriplyDB

CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation

CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation

http://www.wikidata.org/entity/Q34407712

about

C/EBPα in normal and malignant myelopoiesis.High expression of ETS2 predicts poor prognosis in acute myeloid leukemia and may guide treatment decisions.Progression inference for somatic mutations in cancer.HK3 overexpression associated with epithelial-mesenchymal transition in colorectal cancer.

P2860

Q38370875-DB084287-3953-4952-8331-B63576439C50 Q38671635-942ED96B-5174-4625-8372-01132E8081B3 Q38793244-3659421A-0BFC-443F-8118-0D71195FE6FB Q54096044-ADB11CBF-65EE-4D85-8095-3748E9222B0C

P2860

CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation

http://www.wikidata.org/entity/Q34407712

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation

@ast

CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation

@en

CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation

@nl

type

label

CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation

@ast

CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation

@en

CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation

@nl

prefLabel

CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation

@ast

CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation

@en

CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation

@nl

P1433

Q34407712-8724EAC7-4C63-4984-9D43-4F4BDBBC15C1

P1476

Q34407712-C4BEC468-0F79-442B-A337-4F8AFA245D4A

P2093

Q34407712-0BD5ACA6-2F92-4B72-ABC1-E723CE171CE5

Q34407712-45952655-5FA4-422D-B09E-06F99BDB301A

Q34407712-899EF144-A955-464E-92D3-9E7F99A1BAFE

Q34407712-C2960E32-C322-4704-8521-DA0C53F8EAE6

P2860

Q34407712-0B2F7DD8-7570-475D-B325-22F459FFC2E9

Q34407712-15B6E691-FD3B-4924-835C-5C42CDB3889A

Q34407712-299F1669-D75B-490B-A5F5-AB3C5DD85293

Q34407712-2A4A3B93-9112-4697-B13A-FE1C877FBA21

Q34407712-2C7F20AF-11E4-4FD6-9D70-79AA8DD8740B

Q34407712-38B05801-592A-4C55-848A-668ED9DC965F

Q34407712-3CA17421-6A6D-451C-BDAF-DDCE482B39C9

Q34407712-3F378A0B-2E30-40DD-86BF-35695BB1460A

Q34407712-4B5AFFA6-8FC6-4DFE-A71C-965CAB8C5914

Q34407712-4FC4459E-9DB2-45E3-9253-7440DE691020

P2888

Q34407712-AB457F85-4BA6-445B-86DD-6380500ED5CD

P304

Q34407712-057DBEBF-9CEA-4633-A9E3-AA84363BFA3D

P31

Q34407712-F0334010-F783-4A87-A2EA-9BA917F28864

P356

Q34407712-7A36E731-1D23-4F7A-8BD6-C8A1F922E4B4

P407

Q34407712-CC5510C0-922E-48E2-8A98-BF126AD3E9EA

P478

Q34407712-6AB0495A-9B46-4941-A4E8-2EDA34C5BD75

P50

Q34407712-247AEDA0-DF91-4FF2-BF96-D697C671728C

Q34407712-49C9563C-C481-4FDB-9F89-80531F64172B

P577

Q34407712-CF7F8E0F-D571-49CD-B3FD-35308C9471C5

P5875

Q34407712-4F51EC3D-8009-44B3-A61C-10271C44E793

P6179

Q34407712-A5CF730F-A8F2-48A4-8746-588826417CB8

P698

Q34407712-37DAB47C-485E-4279-881F-7E2F8C1A0C59

P932

Q34407712-21D49185-6697-4E4B-90C9-76B9700D7510

P356

P1433

Scientific Reports

P1476

CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation

@en

P2093

Bruce E Torbett

http://www.w3.org/2001/XMLSchema#string

Elena A Federzoni

http://www.w3.org/2001/XMLSchema#string

Gerhard Behre

http://www.w3.org/2001/XMLSchema#string

Martin F Fey

http://www.w3.org/2001/XMLSchema#string

P2860

C/EBPα Dysregulation in AML and ALL

Mammalian Krüppel-like factors in health and diseases

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Compartmentation of hexokinase in human blood cells. Characterization of soluble and particulate enzymes

CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors

Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo.

PU.1 is linking the glycolytic enzyme HK3 in neutrophil differentiation and survival of APL cells.

C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations

Transcription factors in myeloid development: balancing differentiation with transformation.

Disruption of differentiation in human cancer: AML shows the way.

P2888

P304

4261

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SREP04261

http://www.w3.org/2001/XMLSchema#string

P407

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Mario P. Tschan

P577

2014-03-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260446192

http://www.w3.org/2001/XMLSchema#string

P6179

1023300498

http://www.w3.org/2001/XMLSchema#string

P698

24584857

http://www.w3.org/2001/XMLSchema#string

P932

3939455

http://www.w3.org/2001/XMLSchema#string